Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions

References

• Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–1774. doi:10.1002/cncr.2865724648013
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Sarcoma Committee of Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology.Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (Version 2015). Zhonghua Zhong Liu Za Zhi. 2016;38(4):310–320. doi:10.3760/cma.j.issn.0253-3766.2016.04.01327087380
   PubMedGoogle Scholar
• von Mehren M, Randall RL, Benjamin RS 3rd et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(5):536–563. doi:10.6004/jnccn.2018.002529752328
   PubMedGoogle Scholar
• Blay JY. Getting up-to-date in the management of soft tissue sarcoma. Future Oncol. 2018;14(10s):3–13. doi:10.2217/fon-2018-0074
   PubMed Web of Science ®Google Scholar
• Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29(4):857. doi:10.1093/annonc/mdx80729432564
   PubMed Web of Science ®Google Scholar
• Morgan SS, Cranmer LD. Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future. Curr Oncol Rep. 2011;13(4):331–349. doi:10.1007/s11912-011-0182-z21633784
   PubMed Web of Science ®Google Scholar
• Zer A, Prince RM, Amir E, Abdul Razak AR. Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis. Cancer Treat Rev. 2018;63:71–78. doi:10.1016/j.ctrv.2017.12.00329253836
   PubMed Web of Science ®Google Scholar
• Villalobos VM, Byfield SD, Ghate SR, Adejoro O. A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US. Clin Sarcoma Res. 2017;7:18. doi:10.1186/s13569-017-0084-429152166
   PubMed Web of Science ®Google Scholar
• Gronchi AFS, Quagliuolo V, Broto JM, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–822. doi:10.1016/S1470-2045(17)30334-028499583
   PubMed Web of Science ®Google Scholar
• Beatrice Seddon SJS, Whelan J, Leahy M, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(20):1397–1410. doi:10.1016/S1470-2045(17)30622-828882536
   PubMedGoogle Scholar
• Lindner LH, Litiere S, Sleijfer S, et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: an exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Int J Cancer. 2018;142(12):2610–2620. doi:10.1002/ijc.3128629383713
   PubMed Web of Science ®Google Scholar
• Nakano K, Takahashi S. Current molecular targeted therapies for bone and soft tissue sarcomas. Int J Mol Sci. 2018;19(3):739. doi:10.3390/ijms19030739
   PubMed Web of Science ®Google Scholar
• Xie L, Xu J, Sun X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label Phase II clinical trial. Oncologist. 2018. doi:10.1634/theoncologist.2018-0542
   Web of Science ®Google Scholar
• Munhoz RDA SP, Gounder MM, Dickson MA. A phase Ib/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas. Oncologist. 2015;20(11):1245–1246. doi:10.1634/theoncologist.2015-024526449382
   PubMed Web of Science ®Google Scholar
• OB T M, Italiano A, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732–1742. doi:10.1016/S1470-2045(16)30507-127751846
   PubMed Web of Science ®Google Scholar
• Schuetze SBV, Choy E, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123(1):90–97. doi:10.1002/cncr.3037927696380
   PubMed Web of Science ®Google Scholar
• Yihebali Chi ZF, Hong X, Yao Y, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-376629895706
   PubMed Web of Science ®Google Scholar
• Garcia Del Muro X, Maurel J, Martinez TJ, et al. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs. 2018;36(3):468–475. doi:10.1007/s10637-018-0583-z29527631
   PubMed Web of Science ®Google Scholar
• Liu W, Jiang Q, Zhou Y. Advances of systemic treatment for adult soft-tissue sarcoma. Chin Clin Oncol. 2018;7(4):42. doi:10.21037/cco30173532
   PubMed Web of Science ®Google Scholar
• Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018;18(1):396. doi:10.1186/s12885-018-4242-829625604
   PubMedGoogle Scholar
• Baorang Zhu JL, Xie Q, Diao L, Gai L, Yang W. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018;19(3):198–204. doi:10.1080/15384047.2017.141627529261005
   PubMed Web of Science ®Google Scholar
• Park CM, Koh Y, Jeon K, et al. Impact of Eastern Cooperative Oncology Group Performance Status on hospital mortality in critically ill patients. J Crit Care. 2014;29(3):409–413. doi:10.1016/j.jcrc.2014.01.01624603001
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi:10.1016/S1470-2045(14)70063-424618336
   PubMed Web of Science ®Google Scholar
• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–497. doi:10.1016/S0140-6736(16)30587-627291997
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Hiraga H, et al. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016;46(3):248–253. doi:10.1093/jjco/hyv18426864131
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-522595799
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154. doi:10.1186/s12885-015-1584-325885855
   PubMed Web of Science ®Google Scholar
• Feng LZL, Zhao J, Zhao G, et al. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8(38):64471–64480. doi:10.18632/oncotarget.1629328969086
   PubMedGoogle Scholar
• Martin-Liberal J, Lopez-Pousa A, Broto JM, et al. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs. 2014;32(2):287–294. doi:10.1007/s10637-013-9989-923801301
   PubMed Web of Science ®Google Scholar
• Noujaim J, Constantinidou A, Messiou C, et al. Successful ifosfamide rechallenge in soft-tissue sarcoma. Am J Clin Oncol. 2015;1. doi:10.1097/COC.000000000000024323648434
   PubMedGoogle Scholar
• Gronchi A, Jones RL. The value of neoadjuvant chemotherapy in localized high-risk soft-tissue sarcoma of the extremities and trunk. JAMA Oncol. 2018;4(9):1167–1168. doi:10.1001/jamaoncol.2018.139229879269
   PubMed Web of Science ®Google Scholar